HLA-G and anemia: In addition to superior treatment outcomes, the “MGUS-like” subgroup has been associated with favorable baseline clinical characteristics, such as lower frequency of anemia, reduced β2-microglobulin levels, lower serum M-protein concentrations, less frequent high-risk cytogenetic abnormalities, and significantly lower rates of immunoparesis [38,39].